Medicamen Biotech Ltd. announced on February 26, 2025, the approval for the preferential issue of 13,00,000 equity shares at Rs. 530 each, raising up to Rs. 68.90 crores, along with 6,55,000 convertible warrants priced similarly, pending member and regulatory approval.